| Kié Solange Millogo, Bérenger Kaboré, Paul Sondo, Eulalie W. Compaoré, Amélé Fifi Chantal Kouevi, Sié A. Elisée Kambou, Toussaint Rouamba, Adama Kazienga, Hamidou Ilboudo, Marc Christian Tahita, Ismaila Bouda, Karim Derra, Sanata Bamba, Halidou Tinto Trend of N86Y and Y184F Mutations in Pfmdr1 Gene in Children Under Seasonal Malaria Chemoprevention Coverage in Nanoro, Burkina Faso Journal Article In: Acta parasitologica, 2024, ISSN: 1896-1851. @article{Millogo2024,
title = {Trend of N86Y and Y184F Mutations in Pfmdr1 Gene in Children Under Seasonal Malaria Chemoprevention Coverage in Nanoro, Burkina Faso},
author = {Ki\'{e} Solange Millogo and B\'{e}renger Kabor\'{e} and Paul Sondo and Eulalie W. Compaor\'{e} and Am\'{e}l\'{e} Fifi Chantal Kouevi and Si\'{e} A. Elis\'{e}e Kambou and Toussaint Rouamba and Adama Kazienga and Hamidou Ilboudo and Marc Christian Tahita and Ismaila Bouda and Karim Derra and Sanata Bamba and Halidou Tinto},
url = {https://pubmed.ncbi.nlm.nih.gov/39356425/},
doi = {10.1007/S11686-024-00923-X},
issn = {1896-1851},
year = {2024},
date = {2024-01-01},
journal = {Acta parasitologica},
publisher = {Acta Parasitol},
abstract = {Background: Seasonal malaria chemoprevention (SMC) is an effective malaria preventive intervention in sub-Sahara Africa. However, as with any other drug-based intervention, the large-scale deployment of this strategy could lead to Amodiaquine plus Sulfadoxine-Pyrimethamine (AQSP) drug pressure on the circulating parasites population with selection for specific alleles that could compromise the impact of the intervention in the near future. This study aimed to assess the distribution of the Pfmdr1 mutation involved in resistance to AQ before and after the annual campaign of SMC in the health district of Nanoro. Methods: Randomly selected dried blood spots collected prior (n = 100) and after (n = 100) the 2021 SMC campaign were used for the detection of mutation in codons 86 and 184 of the Pfmdr1 gene using a nested PCR with restriction fragment length polymorphism approach. Results: No significant change in the prevalence of Pfmdr1 N86Y mutation was observed before and after the SMC campaign (p = 0.28). The mutant allele 86Y was observed at low prevalences, representing only 2.17% and 6.12%, respectively, before and after the SMC campaign. Patients harboring the mutant Pfmdr1 86Y allele exhibited higher parasite densities compared to patients with the wild-type Pfmdr1 N86 allele (p = 0.04). A significant increase in the prevalence of the mutant allele 184 F was observed in the period before and after the SMC campaign (p = 0.03). Conclusion: This selective pressure needs to be closely monitored in order to preserve the efficacy of this intervention for a long-term period in Burkina Faso.},
keywords = {B\'{e}renger Kabor\'{e}, doi:10.1007/s11686-024-00923-x, Halidou Tinto, Ki\'{e} Solange Millogo, MEDLINE, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, pmid:39356425, PubMed Abstract},
pubstate = {published},
tppubtype = {article}
}
Background: Seasonal malaria chemoprevention (SMC) is an effective malaria preventive intervention in sub-Sahara Africa. However, as with any other drug-based intervention, the large-scale deployment of this strategy could lead to Amodiaquine plus Sulfadoxine-Pyrimethamine (AQSP) drug pressure on the circulating parasites population with selection for specific alleles that could compromise the impact of the intervention in the near future. This study aimed to assess the distribution of the Pfmdr1 mutation involved in resistance to AQ before and after the annual campaign of SMC in the health district of Nanoro. Methods: Randomly selected dried blood spots collected prior (n = 100) and after (n = 100) the 2021 SMC campaign were used for the detection of mutation in codons 86 and 184 of the Pfmdr1 gene using a nested PCR with restriction fragment length polymorphism approach. Results: No significant change in the prevalence of Pfmdr1 N86Y mutation was observed before and after the SMC campaign (p = 0.28). The mutant allele 86Y was observed at low prevalences, representing only 2.17% and 6.12%, respectively, before and after the SMC campaign. Patients harboring the mutant Pfmdr1 86Y allele exhibited higher parasite densities compared to patients with the wild-type Pfmdr1 N86 allele (p = 0.04). A significant increase in the prevalence of the mutant allele 184 F was observed in the period before and after the SMC campaign (p = 0.03). Conclusion: This selective pressure needs to be closely monitored in order to preserve the efficacy of this intervention for a long-term period in Burkina Faso. |
